Editas Medicine, Inc.

Friedberg support ×2 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E71 · 2022-03-05 ▶ 1:23:38

I think that over the long run, we can get the cost of cell therapies below 5,000 bucks. ... And this is kind of the beginning of what will likely be a multi-decade kind of new therapeutic modality that's, you know, accelerating.

Friedberg support ×3 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E68 · 2022-02-19 ▶ 1:12:56

And there are a lot of therapies that are underway right now to actually use gene editing to induce that mutation in people's blood cells and in their bone marrow without needing to give them a whole transplant. ... there are hundreds of cell-based therapies coming to market over the next few years, they're all in late stage clinical trials as well as gene editing.

Friedberg support ×1 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E63 · 2022-01-15 ▶ 1:16:18

Now that we have gene editing and potentially have the ability to grow biological matter in bioreactors, it's going to be tremendous.

Sacks support ×1 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E60 · 2021-12-23 ▶ 1:17:36

Well, you know, I originally had the CRISPR gene in anything, but Chamath already mentioned that.

Chamath support ×2 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E60 · 2021-12-23 ▶ 40:43

My best science breakthrough is that this year, we actually were able to inject in vivo, so in the body genetic code for CRISPR. ... That's pretty incredible stuff that you can make something, put it into your body, and then your body does the work of editing out the bad genes.

Friedberg support ×3 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E59 · 2021-12-17 ▶ 1:09:02

And now the floodgates are open. And this is incredible because the frontiers in RNA over the next decade could change the course of how we treat disease and change the course of outcomes for many diseases, from genetic diseases all the way through to cancers. ... we've now got, I think, a validation in the market and acceptance from consumers that this technology could transform the industry in the same way that Genentech transformed the pharma industry with biologic drugs in the 80s and 90s.

Sacks support ×2 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E42 · 2021-07-30 ▶ 45:21

I mean, I think what it shows is that these COVID vaccines are just the first product, the first breakthrough product of this mRNA technology. There's going to be a lot more.

Chamath support ×3 ▲ on 🤖 In-vivo CRISPR proof point starts programmable biology E42 · 2021-07-30 ▶ 42:30

So I think what we're saying is that we're seeing this platformization, this AWSification of a biological toolchain with things like CRISPR and all of the other modalities that need to stack on top of it so that the next person can view it as a programming problem. ... But this was an enormously important breakthrough because it validated a lot of what CRISPR was beyond a lot of theoretical innovation that up until now was basically what it was known for.